In one paragraphObservational study in Circulation. Heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02980887 (Redefining Pulmonary Hypertension Through Pulmonary Vascular Disease Phenomics), which is not on this map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Redefining Pulmonary Hypertension Through Pulmonary Vascular Disease Phenomics (PVDOMICS)
TypeobservationalSponsorThe Cleveland ClinicRan2016 to 2029Enrolled1,195ConditionsPulmonary Arterial HypertensionArmsNo Intervention
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Yogesh N V ReddyThe Department of Cardiovascular Medicine (Y.N.V.R., R.P.F., A.C.E., W.R.M., B.A.B.), Mayo Clinic, Rochester, MN.ORCID 0000-0001-5322-0902 Robert P FrantzThe Department of Cardiovascular Medicine (Y.N.V.R., R.P.F., A.C.E., W.R.M., B.A.B.), Mayo Clinic, Rochester, MN.ORCID 0000-0003-4128-3978 Alexander C EgbeThe Department of Cardiovascular Medicine (Y.N.V.R., R.P.F., A.C.E., W.R.M., B.A.B.), Mayo Clinic, Rochester, MN.ORCID 0000-0002-8810-3631 William R MirandaThe Department of Cardiovascular Medicine (Y.N.V.R., R.P.F., A.C.E., W.R.M., B.A.B.), Mayo Clinic, Rochester, MN.ORCID 0000-0001-8864-8474 Aneesh K AsokanThe Department of Cardiovascular Medicine (Y.N.V.R., R.P.F., A.C.E., W.R.M., B.A.B.), Mayo Clinic, Rochester, MN.ORCID 0009-0001-0147-4537 Paul M HassounDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD (P.M.H., M.M.).ORCID 0000-0003-0601-4975 Anna R HemnesDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN (A.R.H.).ORCID 0000-0002-2755-5845 Evelyn HornPerkin Heart Failure Center, Division of Cardiology, Weill Cornell Medicine, New York, NY (E.H.).ORCID 0000-0002-5751-9415 Jane A LeopoldDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (J.A.L.).ORCID 0000-0003-0598-8882 Franz RischardDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Arizona, Tucson (F.R.).
Erika B RosenzweigDepartment of Pediatrics and Medicine, Columbia University, New York, NY (E.B.R.).ORCID 0000-0003-4849-214X Nicholas S HillDivision of Pulmonary, Critical Care, and Sleep Medicine, Tufts Medical Center, Boston, MA (N.S.H.).ORCID 0000-0002-8242-8339 Monica MukherjeeDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD (P.M.H., M.M.).ORCID 0000-0001-6088-0773 K Sreekumaran NairThe Division of Endocrinology, Metabolism, Diabetes and Nutrition (A.K.A., K.S.N.), Mayo Clinic, Rochester, MN.
Barry A BorlaugThe Department of Cardiovascular Medicine (Y.N.V.R., R.P.F., A.C.E., W.R.M., B.A.B.), Mayo Clinic, Rochester, MN.ORCID 0000-0001-9375-0596 Funding
Pulmonary Vascular Disease Phenomics Program (PVDOMICS) Data Coordinating CenterU01HL125177 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI BECK, GERALD J, ERZURUM, SERPIL C. · 2014 to 2020
$20.0MPulmonary Hypertension in Left Heart DiseaseR01HL162828 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug, Margaret M Redfield · 2023 to 2026
$3.1MHL-Inorganic Nitrite to Enhance Benefits from Exercise Training in Heart Failure with preserved Ejection FractionR01HL128526 · NHLBI · MAYO CLINIC ROCHESTER · PI BORLAUG, BARRY A. · 2016 to 2019
$2.4MMayo Clinic HeartShare Clinical CenterU01HL160226 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug, Margaret M Redfield · 2021 to 2026
$1.8MIntergrated Endothelial Phenotyping to Redefine Pulmonary HypertensionU01HL125215 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LEOPOLD, JANE A, WAXMAN, AARON B · 2014 to 2018
$1.7MPVDOMICS Defining the Future Fingerprints of Pulmonary Vascular DiseaseU01HL125218 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BERMAN-ROSENZWEIG, ERIKA S., HORN, EVELYN · 2014 to 2018
$1.6MRedefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics: Clinical Centers (CC) (U01).U01HL125205 · NHLBI · MAYO CLINIC ROCHESTER · PI FRANTZ, ROBERT PAUL · 2014 to 2018
$1.5MA molecular phenotype of combined pulmonary hypertensionU01HL125212 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HEMNES, ANNA R, NEWMAN, JOHN HUGHES · 2014 to 2018
$1.5MPhenomic and genomic study to subphenotype Hispanics with pulmonary hypertensionU01HL125208 · NHLBI · UNIVERSITY OF ARIZONA · PI GARCIA, JOE G. N., RISCHARD, FRANZ P · 2014 to 2018
$1.5MHopkins Clinical Center for Pulmonary Vascular Disease Phenomics ProgramU01HL125175 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI HASSOUN, PAUL M., MATHAI, STEPHEN C · 2015 to 2019
$1.1MPeripheral Limitations in Pulmonary Hypertension and Effects of Muscle TrainingK23HL164901 · NHLBI · MAYO CLINIC ROCHESTER · PI Yogesh Nellore Vilambi Reddy · 2023 to 2026
$671kNHLBI NIH HHS K23 HL164901NHLBI NIH HHS R01 HL128526NHLBI NIH HHS R01 HL162828NHLBI NIH HHS U01 HL125175NHLBI NIH HHS U01 HL125177NHLBI NIH HHS U01 HL125205NHLBI NIH HHS U01 HL125208NHLBI NIH HHS U01 HL125212NHLBI NIH HHS U01 HL125215NHLBI NIH HHS U01 HL125218NHLBI NIH HHS U01 HL160226
6 · The paper itselfAbstract
backgroundSome symptomatic patients manifest pulmonary hypertension (PH), despite normal pulmonary vascular resistance and pulmonary artery wedge pressure-a condition termed unclassified PH. Although hypothesized to reflect increased flow as seen in congenital heart disease, broader clinical implications remain unknown.
methodsThe current analysis included pulmonary vascular disease phenomics participants with either no PH or unclassified PH who underwent dynamic right heart catheterization and transpulmonary metabolomics. In a validation cohort, patients with no PH or unclassified PH underwent exercise right heart catheterization. In exploratory cohorts to understand the impact of increased flow, the prevalence of unclassified PH was assessed in (1) adult congenital heart disease and (2) high output heart failure.
resultsThe overall prevalence of unclassified PH in pulmonary vascular disease phenomics (n=1046) and the validation cohort (n=1202) was 7.8% (175/2248), which was comparable to the 6.6% (66/1005) prevalence in adult congenital heart disease (n=1005), and lower than high output heart failure (n=159, prevalence 14.5% [23/159];
conclusionsThe presence of PH without obvious cause most often reflects subclinical left heart and metabolic dysfunction consistent with unrecognized early-stage HFpEF. Dynamic provocation during right heart catheterization can unmask unrecognized HFpEF in over half of unclassified PH, which may help guide appropriate initiation of proven HFpEF therapies to improve symptoms and functional status. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02980887.
Indexed as
Heart Defects, CongenitalHeart FailureHypertension, PulmonaryPulmonary ArteryAdultCardiac CatheterizationFemaleHumansMaleMetabolomicsMiddle AgedPhenotypePrevalencePulmonary Wedge PressureVascular Resistanceheart failurehemodynamicshypertension, pulmonaryphenotypevascular resistance
Identifiers
PMID42318624
PMCPMC13286243
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390